Clinical Trials Logo

Bardet Biedl Syndrome (BBS) clinical trials

View clinical trials related to Bardet Biedl Syndrome (BBS).

Filter by:
  • None
  • Page 1

NCT ID: NCT03746522 Completed - Clinical trials for Bardet Biedl Syndrome (BBS)

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Start date: November 23, 2018
Phase: Phase 3
Study type: Interventional

This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS). The study's primary efficacy endpoint is to evaluate the proportion of participants (≥ 12 years of age at baseline) who lose ≥ 10% of their baseline body weight following approximately (~) 52 weeks of treatment with setmelanotide compared to a historical control rate.